"Pyrroles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Azoles of one NITROGEN and two double bonds that have aromatic chemical properties.
| Descriptor ID |
D011758
|
| MeSH Number(s) |
D03.383.129.578
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrroles".
Below are MeSH descriptors whose meaning is more specific than "Pyrroles".
This graph shows the total number of publications written about "Pyrroles" by people in this website by year, and whether "Pyrroles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 4 | 4 |
| 2003 | 9 | 1 | 10 |
| 2004 | 2 | 1 | 3 |
| 2005 | 5 | 0 | 5 |
| 2006 | 6 | 2 | 8 |
| 2007 | 6 | 3 | 9 |
| 2008 | 9 | 5 | 14 |
| 2009 | 2 | 1 | 3 |
| 2010 | 2 | 1 | 3 |
| 2011 | 8 | 2 | 10 |
| 2012 | 4 | 2 | 6 |
| 2013 | 11 | 2 | 13 |
| 2014 | 4 | 6 | 10 |
| 2015 | 3 | 0 | 3 |
| 2016 | 6 | 3 | 9 |
| 2017 | 4 | 3 | 7 |
| 2018 | 1 | 4 | 5 |
| 2019 | 1 | 2 | 3 |
| 2020 | 2 | 0 | 2 |
| 2021 | 0 | 2 | 2 |
| 2022 | 1 | 2 | 3 |
| 2023 | 0 | 1 | 1 |
| 2024 | 3 | 2 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyrroles" by people in Profiles.
-
Effects of amoxicillin dosage on cure rate, gut microbiota, and?antibiotic resistome in vonoprazan and amoxicillin dual therapy for Helicobacter pylori: a multicentre, open-label, non-inferiority randomised controlled trial. Lancet Microbe. 2025 Mar; 6(3):100975.
-
Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profiling. Ann Oncol. 2025 Apr; 36(4):414-425.
-
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer. Breast Cancer Res Treat. 2025 Feb; 209(3):487-492.
-
Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. JCO Precis Oncol. 2024 Jun; 8:e2400103.
-
Fourteen-day vonoprazan-based bismuth quadruple therapy for H. pylori eradication in an area with high clarithromycin and levofloxacin resistance: a prospective randomized study (VQ-HP trial). Sci Rep. 2024 04 18; 14(1):8986.
-
Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1-4 Inhibitor: Pooled Safety Analysis of 469 Patients. Clin Cancer Res. 2024 Apr 15; 30(8):1466-1477.
-
Remdesivir for COVID-19 in Hospitalized Children: A Phase 2/3 Study. Pediatrics. 2024 Mar 01; 153(3).
-
Inhibition of CSF1R and KIT With Pexidartinib Reduces Inflammatory Signaling and Cell Viability in Endometriosis. Endocrinology. 2024 Feb 20; 165(4).
-
KIT-mutated pediatric core-binding factor systemic mastocytosis-acute myeloid leukemia treated with avapritinib and decitabine. Pediatr Blood Cancer. 2024 Apr; 71(4):e30898.
-
Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer. Sci Rep. 2023 11 18; 13(1):20223.